Quantification of clonal circulating plasma cells in relapsed multiple myeloma

British Journal of Haematology

Volumn 167, Issue 4, 2014, Pages 500-505

  Gonsalves, Wilson I ^a   Morice, William G ^a   Rajkumar, Vincent ^a   Gupta, Vinay ^a   Timm, Michael M ^a   Dispenzieri, Angela ^a   Buadi, Francis K ^a   Lacy, Martha Q ^a   Singh, Preet P ^a   Kapoor, Prashant ^a   Gertz, Morie A ^a   Kumar, Shaji K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Circulating plasma cells; Multiple myeloma; Survival

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLONAL CIRCULATING PLASMA CELL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASTIC CELLS, CIRCULATING; PLASMA CELLS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84916197779     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13067     Document Type: Article

References (23)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine, 335, 91-97.
2. Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467-472.
3. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine, 348, 1875-1883.
4. Dingli, D., Nowakowski, G.S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Rajkumar, S.V., Greipp, P.R., Litzow, M.R., Gastineau, D.A., Witzig, T.E. & Gertz, M.A. (2006) Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood, 107, 3384-3388.
5. Durie, B.G., Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
6. Egan, J.B., Shi, C.X., Tembe, W., Christoforides, A., Kurdoglu, A., Sinari, S., Middha, S., Asmann, Y., Schmidt, J., Braggio, E., Keats, J.J., Fonseca, R., Bergsagel, P.L., Craig, D.W., Carpten, J.D. & Stewart, A.K. (2012) Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood, 120, 1060-1066.
7. Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., Teague, J.W., Campbell, P.J., Stratton, M.R. & Futreal, P.A. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research, 39, D945-D950.
8. Gonsalves, W.I., Rajkumar, S.V., Gupta, V., Morice, W.G., Timm, M.M., Singh, P.P., Dispenzieri, A., Buadi, F.K., Lacy, M.Q., Kapoor, P., Gertz, M.A. & Kumar, S.K. (2014) Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia, doi: 10.1038/leu.2014.98
9. Kapoor, P., Fonseca, R., Rajkumar, S.V., Sinha, S., Gertz, M.A., Stewart, A.K., Bergsagel, P.L., Lacy, M.Q., Dingli, D.D., Ketterling, R.P., Buadi, F., Kyle, R.A., Witzig, T.E., Greipp, P.R., Dispenzieri, A. & Kumar, S. (2010) Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clinic proceedings. Mayo Clinic, 85, 532-537.
10. Kumar, S.K., Therneau, T.M., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Witzig, T.E., Lust, J.A., Larson, D.R., Kyle, R.A. & Greipp, P.R. (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clinic proceedings. Mayo Clinic, 79, 867-874.
11. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008a) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
12. Kumar, S., Mahmood, S.T., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Buadi, F.K., Dingli, D., Rajkumar, S.V., Litzow, M.R. & Gertz, M.A. (2008b) Impact of early relapse after auto-SCT for multiple myeloma. Bone marrow transplantation, 42, 413-420.
13. Kumar, S.K., Lee, J.H., Lahuerta, J.J., Morgan, G., Richardson, P.G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., LeLeu, X., Hulin, C., Klein, S.K., Sonneveld, P., Siegel, D., Bladé, J., Goldschmidt, H., Jagannath, S., Miguel, J.S., Orlowski, R., Palumbo, A., Sezer, O., Rajkumar, S.V. & Durie, B.G. (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia, 26, 149-157.
14. Migkou, M., Kastritis, E., Roussou, M., Gkotzamanidou, M., Gavriatopoulou, M., Nikitas, N., Mparmparoussi, D., Matsouka, C., Gika, D., Terpos, E. & Dimopoulos, M.A. (2011) Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. European journal of haematology, 87, 323-329.
15. Mikhael, J.R., Dingli, D., Roy, V., Reeder, C.B., Buadi, F.K., Hayman, S.R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R.A., Lin, Y., Russell, S.J., Kumar, S., Bergsagel, P.L., Zeldenrust, S.R., Leung, N., Drake, M.T., Kapoor, P., Ansell, S.M., Witzig, T.E., Lust, J.A., Dalton, R.J., Gertz, M.A., Stewart, A.K., Rajkumar, S.V., Chanan-Khan, A. & Lacy, M.Q. (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic proceedings. Mayo Clinic, 88, 360-376.
16. Mishima, Y., Lohr, J., Tai, Y., Flores, L., Aljawai, Y., Laubacj, J.P., Richardson, P.C., Roccaro, A.M., Anderson, K.C., Munshi, N.C. & Ghobrial, I.M. (2013) Molecular analysis of circulating tumor cells identifies mutations that are distinct from those present in the bone marrow of patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts), 122, 533.
17. Nowakowski, G.S., Witzig, T.E., Dingli, D., Tracz, M.J., Gertz, M.A., Lacy, M.Q., Lust, J.A., Dispenzieri, A., Greipp, P.R., Kyle, R.A. & Rajkumar, S.V. (2005) Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood, 106, 2276-2279.
18. Paiva, B., Paino, T., Sayagues, J.M., Garayoa, M., San-Segundo, L., Martín, M., Mota, I., Sanchez, M.L., Bárcena, P., Aires-Mejia, I., Corchete, L., Jimenez, C., Garcia-Sanz, R., Gutierrez, N.C., Ocio, E.M., Mateos, M.V., Vidriales, M.B., Orfao, A. & San Miguel, J.F. (2013) Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood, 122, 3591-3598.
19. Rawstron, A.C., Owen, R.G., Davies, F.E., Johnson, R.J., Jones, R.A., Richards, S.J., Evans, P.A., Child, J.A., Smith, G.M., Jack, A.S. & Morgan, G.J. (1997) Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. British journal of haematology, 97, 46-55.
20. Richardson, P., Mitsiades, C., Schlossman, R., Ghobrial, I., Hideshima, T., Chauhan, D., Munshi, N. & Anderson, K. (2007) The treatment of relapsed and refractory multiple myeloma. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 317-323.
21. Teoh, G. & Anderson, K.C. (1997) Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematology/oncology clinics of North America, 11, 27-42.
22. Witzig, T.E., Dhodapkar, M.V., Kyle, R.A. & Greipp, P.R. (1993) Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer, 72, 108-113.
23. Witzig, T.E., Kimlinger, T.K., Ahmann, G.J., Katzmann, J.A. & Greipp, P.R. (1996) Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry, 26, 113-120.